How 10x Genomics Stock Has Been Trading Recently

With no single headline event driving attention today, 10x Genomics (TXG) is on investors’ radar mainly because of its recent share performance. The stock has seen a 1% decline over the past day and gains over the past month.

Zooming out, the recent 1-day share price decline sits against a 34.9% year to date share price return and a very large 159.79% 1-year total shareholder return, while the 5-year total shareholder return of 83.59% loss shows how mixed the longer term experience has been for holders.

If 10x Genomics has you thinking about where else momentum and risk are shifting, this is a good moment to see what the market is pricing into 35 healthcare AI stocks

With TXG trading at a discount to both one valuation estimate and the average analyst price target, yet carrying a mixed multi year return record and ongoing losses, is this a genuine entry point, or is the market already pricing in future growth?

Most Popular Narrative: 11.3% Overvalued

At a last close of $22.42 versus a narrative fair value of $20.14, the most followed view sees 10x Genomics as pricing in a premium and hinges heavily on product adoption and funding trends.

Adoption of new lower-cost consumables (like GEM-X Flex and Universal On Chip Multiplex) is increasing reaction volumes and enabling scale, positioning 10x Genomics to capture growing demand in single-cell and multiomic analysis driven by precision medicine, likely supporting long-term revenue and recurring, high-margin consumables sales.

Wondering what kind of revenue trajectory, margin shift, and future earnings multiple are embedded in that fair value, and how analysts connect those dots over time.

Result: Fair Value of $20.14 (OVERVALUED)

However, there are clear pressure points, including softer academic and government research budgets and ongoing operating losses, that could challenge the current argument that the stock is overvalued.

Another Way To Look At TXG’s Value

The narrative consensus tags 10x Genomics as 11.3% overvalued at a fair value of $20.14. In contrast, the SWS DCF model points in the opposite direction, with a future cash flow value of $34.65 and TXG trading at a 35.3% discount. Which story do you think is closer to reality?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out 10x Genomics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed signals on price and fundamentals so far, so if this has raised questions, act while the data is fresh and weigh both sides for yourself with 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If TXG has sparked fresh questions, do not stop here. Widen your scope and pressure test your thinking across a broader set of stocks with targeted screeners.

• Zero in on quality at a discount by checking companies highlighted in the 51 high quality undervalued stocks that may align better with your risk and return expectations.
• Prioritise resilience and fewer surprises by reviewing the 72 resilient stocks with low risk scores so you can focus on businesses with more stable risk profiles.
• Hunt for lesser known opportunities with strong fundamentals using the screener containing 23 high quality undiscovered gems before other investors start paying closer attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.